BRAF V600E mutation and clinicopathologic analysis of papillary thyroid carcinoma in Air Force flight peronnel
10.7644/j.issn.1674-9960.2024.11.006
- VernacularTitle:空军飞行人员甲状腺乳头状癌BRAF V600E突变及临床病理分析
- Author:
Guangxin ZHOU
1
;
Li XIAO
;
Huijuan ZHU
;
Junjie DU
;
Li CUI
;
Guoli GU
;
Haojun GUAN
;
Yukun TAO
;
Huijing ZHU
;
Jinzheng HOU
;
Da ZHANG
Author Information
1. 空军军医大学空军特色医学中心内分泌科,北京 100142
- Keywords:
v-raf murine sarcoma viral oncogene homolog B1 V600E;
genetic mutation;
papillary thyroid cancer;
Air Force flight personnel
- From:
Military Medical Sciences
2024;48(11):838-842
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the characteristics and clinicopathology of v-raf murine sarcoma viral oncogene homolog Bl(BRAF)V600E mutations in papillary thyroid carcinoma(PTC)in Air Force flight personnel.Methods Data of cases and test results of BRAF V600E mutation were collected from Air Force aviators pathologically diagnosed with PTC.A univariate analysis of the relationship between BRAF V600E mutations and clinicopathologic features was performed.Results The overall rate of BRAF V600E mutations among 55 PTC flight crew members was 70.91％.The univariate analysis showed that the number of lymph node metastases in the BRAF V600E mutated group was larger than in the BRAF V600E unmutated group,and the proportion of BRAF V600E mutations in flight crews at intermediate risk of recurrence was higher than that in those at low risk of recurrence(P＜0.05).The presence or absence of BRAF V600E mutations did not affect the results of medical evaluation of PTC in flight personnel.Conclusion The rate of PTC BRAF V600E mutations in Air Force flight crews is similar to that of the general Chinese population.BRAF V600E mutations are associated with an increased number of lymph node metastases and risk of recurrence,and follow-up is recommended for flight personnel with PTC,especially those with BRAF V600E mutations.
